The Next Science Limited (ASX: NXS) share price is up 47 cents or 12.5% to $4.23 today despite the medical science business not releasing any specific news to the market.
Since its April 2019 initial public offering at just $1 per share the stock has gone absolutely gangbusters on investor excitement over the potential of its four FDA approved Xbio products used to treat wounds or lacerations on patients during or after surgery.
The biofilm products basically help kill bacteria to prevent infections and given the problems with hospital infections globally the patented products have a potentially large addressable market.
The group has another three potential products for the treatment of sinus surgery, minimally invasive surgeries, and ear surgery that it reports are at or towards the advanced stage of the approval process.
It also has a pipeline of other early stage products that it expects may be approved for commercialisation anytime between 2021 and 2023.
This all sounds exciting, but punters should consider that with 102.6 million shares on issue Next Science now has a market cap of $434 million yet posted a whopping net loss of US$14.8 million on revenue of just US$2.73 million for FY 2018.
As such its financials and rocketing share price look mirror opposites of each other.
